Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Sep-Oct;22(4):670-5.

HIV preexposure prophylaxis in the real world

Demetre C Daskalakis  1
Affiliations
Case Reports

HIV preexposure prophylaxis in the real world

Demetre C Daskalakis. Top Antivir Med. 2014 Sep-Oct.

Abstract

According to evolving guidelines, candidates for HIV preexposure prophylaxis (PrEP) include HIV-uninfected men who have sex with men who engage in condomless anal intercourse, individuals in HIV-serodifferent sexual relationships, those with frequent anogenital sexually transmitted infections, and those who have received repeated nonoccupational postexposure prophylaxis treatment courses. In the real-world setting, indications for PrEP and management of PrEP candidates and patients may be less than clear-cut. Factors to be considered when assessing candidacy for PrEP and maximizing efficacy of treatment are discussed. This article summarizes a presentation by Demetre C. Daskalakis, MD, MPH, at the IAS-USA continuing education program held in Los Angeles, California, in April 2014.

PubMed Disclaimer

Conflict of interest statement

Financial affiliations in the past 12 months: Dr Daskalakis has no relevantfinancial affiliations to disclose.

Figures

Figure 1.
Figure 1.
Number of patients needed to treat for 1 year to prevent 1 case of HIV acquisition in preexposure prophylaxis (PrEP) trials or 1 cardiovascular event with statin use for primary prevention. CAPRISA indicates Center for the AIDS Program of Research in South Africa; FTC, emtricitabine; iPrEx, Chemoprophylaxis for HIV Prevention in Men; TDF, tenofovir disoproxil fumarate. Adapted with permission from Glidden.
See this image and copyright information in PMC

References

    1. HIV Clinical Resource. Guidance for the use of pre-exposure prophylaxis (PrEP) to prevent HIV transmission. http://www. hivguidelines.org/clinical-guidelines/pre-exposure-prophylax.... Accessed on October 2, 2014.
    1. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. JAIDS. 2010;53(4):537-543. - PubMed
    1. Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis. 2013;57(8): 1203-1209. - PubMed
    1. Heuker J, Sonder GJ, Stolte I, Geskus R, van den Hoek A. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS. 2012;26(4):505-512. - PubMed
    1. Sonder GJ, Prins JM, Regez RM, et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex Transm Dis. 2010;37(11): 681-686. - PubMed

Publication types

MeSH terms